Theravance Biopharma Inc Long-term Investment Intensity
Theravance Biopharma Inc long-term investment intensity. Theravance Biopharma Inc (0TB) has a Long-term Investment Intensity of 0.7% as of September 2025. Long-term investments of €3.03 Million represent 0.7% of total assets of €415.46 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Read 0TB current and long-term liabilities for a breakdown of total debt and financial obligations.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Long-term Investment Intensity of Theravance Biopharma Inc (2014–2021)
Long-term investment intensity of Theravance Biopharma Inc from 2014 to 2021. This chart shows how Theravance Biopharma Inc's Long-term Investment Intensity has evolved across 8 annual periods from 2014 to 2021. As of September 2025, the intensity stands at 0.7%, reflecting long-term investments of €3.03 Million against total assets of €415.46 Million EUR.
Theravance Biopharma Inc Long-term Investment Intensity by Year (2014–2021)
Theravance Biopharma Inc long-term investment intensity by year from 2014 to 2021. The table below presents the year-by-year Long-term Investment Intensity for Theravance Biopharma Inc from 2014 to 2021, covering 8 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Theravance Biopharma Inc's balance sheet.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2021 | 18.0% | €67.54 Million | €374.82 Million | ▲ +15.3 pp |
| 2020 | 2.7% | €12.75 Million | €469.06 Million | ▲ +1.5 pp |
| 2019 | 1.2% | €4.99 Million | €408.83 Million | ▼ -0.9 pp |
| 2018 | 2.1% | €11.87 Million | €560.24 Million | ▼ -7.3 pp |
| 2017 | 9.4% | €41.59 Million | €441.40 Million | ▼ -6.2 pp |
| 2016 | 15.6% | €99.56 Million | €639.25 Million | ▼ -1.4 pp |
| 2015 | 16.9% | €50.86 Million | €300.12 Million | ▲ +1.7 pp |
| 2014 | 15.2% | €51.40 Million | €337.77 Million | — |